Cited by 1,305interferon and immune responsesImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.

Type I interferons in anticancer immunity

Zitvogel, Laurence, Galluzzi, Lorenzo, Kepp, Oliver, Smyth, Mark J., Kroemer, Guido·2015·Nature Reviews Immunology

Open this paper in CoChat — free account

Abstract

Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with favourable disease outcome in several cohorts of patients with cancer. Finally, new anticancer immunotherapies are being developed that are based on recombinant type I IFNs, type I IFN-encoding vectors and type I IFN-expressing cells.

Integrity signals

Registry

Crossref · 10.1038/nri3845

Cites

128 of 128 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Self-citation
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,235
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
STING is a direct innate immune sensor of cyclic di-GMP
Burdette, D. L., Monroe, K. M., Sotelo-Troha, K., Iwig, J. S., Eckert, B., Hyodo, M., Hayakawa, Y., & Vance, R. E. (2011) · Nature · doi:10.1038/nature10429 · Cited by 1,570
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Self-citation
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,438
Self-citation
Viruses and interferon: a fight for supremacy
Katze, M. G., He, Y., & Gale, M. (2002) · Nature Reviews Immunology · doi:10.1038/nri888 · Cited by 1,419
Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042
Self-citation
Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production
White, M. J., McArthur, K., Metcalf, D., Lane, R. M., Cambier, J. C., Herold, M. J., van Delft, M. F., Bedoui, S., Lessene, G., Ritchie, M. E., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.036 · Cited by 983
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 901
Self-citation
The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon–Dependent Innate and Adaptive Immunity
Burnette, B., Liang, H. L., Lee, Y., Chlewicki, L. K., Khodarev, N. N., Weichselbaum, R. R., Fu, Y., & Auh, S. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2820 · Cited by 883
Apoptotic Caspases Prevent the Induction of Type I Interferons by Mitochondrial DNA
Rongvaux, A., Jackson, R., Harman, C. C. D., Li, T., West, A. P., de Zoete, M. R., Wu, Y., Yordy, B., Lakhani, S. A., Kuan, C.-Y., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.037 · Cited by 847
Type I interferon: friend or foe?
Trinchieri, G. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20101664 · Cited by 838
Alpha Interferon for Induction of Remission in Hairy-Cell Leukemia
Quesada, J. R., Reuben, J. M., Manning, J. T., Hersh, E. M., & Gutterman, J. U. (1984) · New England Journal of Medicine · doi:10.1056/nejm198401053100104 · Cited by 817
Identification of a dendritic cell receptor that couples sensing of necrosis to immunity
Sancho, D., Joffre, O. P., Keller, A. M., Rogers, N. C., Martínez, D., Hernanz-Falcón, P., Rosewell, I., & Sousa, C. R. E. (2009) · Nature · doi:10.1038/nature07750 · Cited by 750
Mitochondria: master regulators of danger signalling
Galluzzi, L., Kepp, O., & Kroemer, G. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3479 · Cited by 733
Self-citation
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
Plasmacytoid Dendritic Cells: Recent Progress and Open Questions
Reizis, B., Bunin, A., Ghosh, H. S., Lewis, K. L. T., & Sisirak, V. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101345 · Cited by 680
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C. D., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 653
Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaAin Chronic Myelogenous Leukemia
Talpaz, M., Kantarjian, H. M., McCredie, K. B., Trujillo, J. M., Keating, M. J., & Gutterman, J. U. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604243141701 · Cited by 644
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
Eggermont, A. M. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H. J., Marsden, J. R., Punt, C. J. A., Salès, F., Gore, M. E., MacKie, R. M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61033-8 · Cited by 639
RNA recognition and signal transduction by RIG‐I‐like receptors
Yoneyama, M., & Fujita, T. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00727.x · Cited by 595
IFN-α and IL-10 Induce the Differentiation of Human Type 1 T Regulatory Cells
Levings, M. K., Sangregorio, R., Galbiati, F., Squadrone, S., Malefyt, R. D. W., & Roncarolo, M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5530 · Cited by 595
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G. W., Xiao, W., Powell, J. I., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 541
Direct Effects of Type I Interferons on Cells of the Immune System
Hervás‐Stubbs, S., Perez‐Gracia, J. L., Rouzaut, A., Sanmamed, M. F., Bon, A. L., & Melero, I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1114 · Cited by 535
Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities
Jonasch, E., & Haluska, F. G. (2001) · The Oncologist · doi:10.1634/theoncologist.6-1-34 · Cited by 520
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Self-citation
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
Bidwell, B. N., Slaney, C. Y., Withana, N. P., Forster, S., Cao, Y., Loi, S., Andrews, D., Mikeska, T., Mangan, N. E., Samarajiwa, S. A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2830 · Cited by 487
Self-citation
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J. M. B., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 481
Self-citation
Autophagy and cellular immune responses
Ma, Y., Galluzzi, L., Zitvogel, L., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.017 · Cited by 447
Self-citation
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci‐Bresler, A., Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004095 · Cited by 400
F-Actin Is an Evolutionarily Conserved Damage-Associated Molecular Pattern Recognized by DNGR-1, a Receptor for Dead Cells
Ahrens, S., Zelenay, S., Sancho, D., Hanč, P., Kjær, S., Feest, C., Fletcher, G., Durkin, C. H., Postigo, A. A., Skehel, M. J., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.008 · Cited by 393
5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma
Poeck, H., Besch, R., Maihoefer, C., Renn, M., Tormo, D., Morskaya, S. S., Kirschnek, S., Gaffal, E., Landsberg, J., Hellmuth, J., et al. (2008) · Nature Medicine · doi:10.1038/nm.1887 · Cited by 387
Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression
Sisirak, V., Faget, J., Gobert, M., Goutagny, N., Vey, N., Treilleux, I., Renaudineau, S., Poyet, G., Labidi‐Galy, S. I., Goddard‐Léon, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3468 · Cited by 377
Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons
Gregorio, J., Meller, S., Conrad, C., Di Nardo, A., Homey, B., Lauerma, A., Arai, N., Gallo, R. L., DiGiovanni, J., & Gilliet, M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20101102 · Cited by 367
PRIMARY SEX-RATIO AND SIZE OF FAMILY
Shokeir, M. H. K. (1970) · The Lancet · doi:10.1016/s0140-6736(70)90607-0 · Cited by 366
Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis
Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362
Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function
Swann, J. B., Hayakawa, Y., Zerafa, N., Sheehan, K. C. F., Scott, B., Schreiber, R. D., Hertzog, P. J., & Smyth, M. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7540 · Cited by 340
Self-citation
Production of type I interferons
Asselin‐Paturel, C., & Trinchieri, G. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051395 · Cited by 304
Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells
Drobits, B., Holcmann, M., Amberg, N., Swiecki, M. K., Grundtner, R., Hammer, M., Colonna, M., & Sibilia, M. C. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61034 · Cited by 295
The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice
Zelenay, S., Keller, A. M., Whitney, P. G., Schraml, B. U., Deddouche, S., Rogers, N. C., Schulz, O., Sancho, D., & Sousa, C. R. E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60644 · Cited by 290
Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
Eggermont, A. M. M., Suciu, S., Testori, A., Santinami, M., Kruit, W. H. J., Marsden, J. R., Punt, C. J. A., Salès, F., Dummer, R., Robert, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.3799 · Cited by 278
INTERFERON THERAPY IN MYELOMATOSIS
Mellstedt, H., Björkholm, M., Johansson, B., Åhre, A., Holm, G., & Strander, H. A. (1979) · The Lancet · doi:10.1016/s0140-6736(79)90770-0 · Cited by 275
Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
Yang, X., Zhang, X., Fu, M. L., Weichselbaum, R. R., Gajewski, T. F., Guo, Y., & Fu, Y. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.004 · Cited by 274
Treatment of Advanced Non-Hodgkin's Lymphoma with Recombinant Leukocyte a Interferon
Foon, K. A., Sherwin, S. A., Abrams, P. G., Longo, D. L., Fer, M. F., Stevenson, H. C., Ochs, J. J., Bottino, G. C., SCHOENBERGER, C., Zeffren, J., et al. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411013111803 · Cited by 274
Structural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1
de Weerd, N. A., Vivian, J. P., Nguyen, T. K., Mangan, N. E., Gould, J. A., Braniff, S.-J., Zaker-Tabrizi, L., Fung, K. Y., Forster, S. C., Beddoe, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2667 · Cited by 267
Interferons and Their Stimulated Genes in the Tumor Microenvironment
Cheon, H., Borden, E. C., & Stark, G. R. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.002 · Cited by 261
Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., Gaffal, E., Steitz, J., Tolba, R. H., Kalinke, U., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0458 · Cited by 261
Gene Signature in Melanoma Associated With Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy
Gajewski, T. F., Louahed, J., & Brichard, V. G. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacbd8 · Cited by 250
Mycobacterium tuberculosis Triggers Host Type I IFN Signaling To Regulate IL-1β Production in Human Macrophages
Novikov, A., Cardone, M., Thompson, R. W., Shenderov, K., Kirschman, K. D., Mayer-Barber, K. D., Myers, T. G., Rabin, R. L., Trinchieri, G., Sher, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100926 · Cited by 246
Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses
Moschos, S. J., Edington, H. D. J., Land, S. R., Rao, U. N. M., Jukic, D. M., Shipe-Spotloe, J. M., & Kirkwood, J. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2498 · Cited by 242
Type I Interferon Protects Antiviral CD8+ T Cells from NK Cell Cytotoxicity
Xu, H. C., Grusdat, M., Pandyra, A. A., Polz, R., Huang, J., Sharma, P., Deenen, R., Köhrer, K., Rahbar, R., Diefenbach, A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.004 · Cited by 232
Type I Interferons Protect T Cells against NK Cell Attack Mediated by the Activating Receptor NCR1
Crouse, J., Bedenikovic, G., Wiesel, M., Ibberson, M. R., Xénarios, I., von Laer, D., Kalinke, U., Vivier, É., Jonjić, S., & Oxenius, A. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.003 · Cited by 229
Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses
Chiba, S., Ikushima, H., Ueki, H., Yanai, H., Kimura, Y., Hangai, S., Nishio, J., Negishi, H., Tamura, T., Saijo, S., et al. (2014) · eLife · doi:10.7554/elife.04177 · Cited by 222
Hepatic RIG-I Predicts Survival and Interferon-α Therapeutic Response in Hepatocellular Carcinoma
Hou, J., Zhou, Y., Zheng, Y., Fan, J., Zhou, W., Ng, I. O., Sun, H., Qin, L., Qiu, S., Lee, J. M. F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.011 · Cited by 221
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera
Mullally, A., Bruedigam, C., Poveromo, L., Heidel, F. H., Purdon, A. S., Vu, T., Austin, R. J., Heckl, D., Breyfogle, L. J., Kuhn, C. P., et al. (2013) · Blood · doi:10.1182/blood-2012-05-432989 · Cited by 200
Copy Number Loss of the Interferon Gene Cluster in Melanomas Is Linked to Reduced T Cell Infiltrate and Poor Patient Prognosis
Linsley, P. S., Speake, C., Whalen, E., & Chaussabel, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109760 · Cited by 194
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
Simonsson, B., Gedde‐Dahl, T., Markevärn, B., Remes, K., Stentoft, J., Almqvist, A., Björeman, M., Flogegård, M., Koskenvesa, P., Lindblom, A., et al. (2011) · Blood · doi:10.1182/blood-2011-02-336685 · Cited by 194
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation
Stewart, C. A., Metheny, H., Iida, N., Smith, L., Hanson, M. L., Steinhagen, F., Leighty, R. M., Roers, A., Karp, C. L., Müller, W., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65180 · Cited by 179
Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
Burchert, A., Müller, M. C., Kostrewa, P., Erben, P., Bostel, T., Liebler, S., Hehlmann, R., Neubauer, A., & Hochhaus, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5075 · Cited by 177
Lenalidomide efficacy in activated B ‐cell‐like subtype diffuse large B ‐cell lymphoma is dependent upon IRF 4 and cereblon expression
Zhang, L., Kosek, J., Wang, M., Heise, C. C., Schafer, P. H., & Chopra, R. (2012) · British Journal of Haematology · doi:10.1111/bjh.12172 · Cited by 172
Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma
Tarhini, A. A., Cherian, J., Moschos, S. J., Tawbi, H. A., Shuai, Y., Gooding, W. E., Sander, C., & Kirkwood, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.5394 · Cited by 148
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
Talpaz, M., Hehlmann, R., Quintás‐Cardama, A., Mercer, J., & Cortes, J. E. (2012) · Leukemia · doi:10.1038/leu.2012.313 · Cited by 145
The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse
Lesinski, G. B., Anghelina, M. I., Zimmerer, J. M., Bakalakos, T., Badgwell, B. D., Parihar, R., Hu, Y., Becknell, B., Abood, G. J., Chaudhury, A. R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16603 · Cited by 135
CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice
Meixlsperger, S., Leung, C. S. K., Rämer, P. C., Pack, M., Vanoaica, L. D., Breton, G., Pascolo, S., Salazar, A. Μ., Dzionek, A., Schmitz, J., et al. (2013) · Blood · doi:10.1182/blood-2012-12-473413 · Cited by 128
Cutting Edge: DNA Sensing via the STING Adaptor in Myeloid Dendritic Cells Induces Potent Tolerogenic Responses
Huang, L., Li, L., Lemos, H. D. P., Chandler, P., Pacholczyk, G. A., Baban, B., Barber, G. N., Hayakawa, Y., McGaha, T. L., Ravishankar, B., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301419 · Cited by 127
Trial Watch
Aranda, F., Vacchelli, E., Eggermont, A. M. M., Galon, J., Fridman, W. H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27297 · Cited by 116
Self-citation
Genetic Engineering of Hematopoiesis for Targeted IFN-α Delivery Inhibits Breast Cancer Progression
Escobar, G., Moi, D., Ranghetti, A., Baydin, P. O., Squadrito, M. L., Kajaste‐Rudnitski, A., Bondanza, A., Gentner, B., Palma, M. D., Mazzieri, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3006353 · Cited by 114
Interferon-α Suppresses cAMP to Disarm Human Regulatory T Cells
Bacher, N., Raker, V., Hofmann, C., Graulich, E., Schwenk, M., Baumgrass, R., Bopp, T., Zechner, U., Merten, L., Becker, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3788 · Cited by 111
IFN-α Skews Monocytes into CD56+-Expressing Dendritic Cells with Potent Functional Activities In Vitro and In Vivo
Papewalis, C., Jacobs, B., Wuttke, M., Ullrich, E., Baehring, T., Fenk, R. R., Willenberg, H. S., Schinner, S., Cohnen, M., Seißler, J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1462 · Cited by 107
Type I interferon signalling in the intestinal epithelium affects Paneth cells, microbial ecology and epithelial regeneration
Tschurtschenthaler, M., Wang, J., Fricke, C., Fritz, T. M. J., Niederreiter, L., Adolph, T. E., Sarcevic, E., Künzel, S., Offner, F. A., Kalinke, U., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305863 · Cited by 105
How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)
Pardanani, A. (2013) · Blood · doi:10.1182/blood-2013-01-453183 · Cited by 101
How I treat polycythemia vera
Passamonti, F. (2012) · Blood · doi:10.1182/blood-2012-02-366054 · Cited by 95
Cyclophosphamide Induces a Type I Interferon–Associated Sterile Inflammatory Response Signature in Cancer Patients' Blood Cells: Implications for Cancer Chemoimmunotherapy
Moschella, F., Torelli, G. F., Valentini, M., Urbani, F., Buccione, C., Petrucci, M. T., Natalino, F., Belardelli, F., Foà, R., & Proietti, E. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3666 · Cited by 87
Therapeutic Activity of High-Dose Intratumoral IFN-β Requires Direct Effect on the Tumor Vasculature
Spaapen, R. M., Leung, M. Y. K., Fuertes, M. B., Kline, J. P., Zhang, L., Zheng, Y., Fu, Y., Luo, X., Cohen, K. S., & Gajewski, T. F. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401109 · Cited by 86
High efficiency cell-specific targeting of cytokine activity
Garcin, G., Paul, F., Staufenbiel, M., Bordat, Y., der Heyden, J. V., Wilmes, S., Cartron, G., Apparailly, F., Koker, S. D., Piehler, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms4016 · Cited by 86
Trial Watch
Aranda, F., Vacchelli, E., Obrist, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Cremer, I., ter Meulen, J. H., Zitvogel, L., Kroemer, G., et al. (2014) · OncoImmunology · doi:10.4161/onci.29179 · Cited by 85
Self-citation
Trial Watch
Vacchelli, E., Aranda, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27048 · Cited by 82
Self-citation
Intratumoral Mediated Immunosuppression is Prognostic in Genetically Engineered Murine Models of Glioma and Correlates to Immunotherapeutic Responses
Kong, L.-Y., Wu, A., Doucette, T. A., Wei, J., Priebe, W., Fuller, G. N., Qiao, W., Sawaya, R. A., Rao, G., & Heimberger, A. B. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1693 · Cited by 80
CpG ODN Nanorings Induce IFNα from Plasmacytoid Dendritic Cells and Demonstrate Potent Vaccine Adjuvant Activity
Gungor, B., Yağcı, F. C., Tincer, G., Bayyurt, B., Alpdundar, E., Yildiz, S., Özcan, M., Gürsel, İ., & Gürsel, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007909 · Cited by 79
Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity
der Jeught, K. V., Joe, P. T., Bialkowski, L., Heirman, C., Daszkiewicz, L., Liechtenstein, T., Escors, D., Thielemans, K., & Breckpot, K. (2014) · Oncotarget · doi:10.18632/oncotarget.2463 · Cited by 79
Type I-IFNs control GVHD and GVL responses after transplantation
Robb, R. J., Kreijveld, E., Kuns, R. D., Wilson, Y. A., Olver, S. D., Don, A. L. J., Raffelt, N. C., de Weerd, N. A., Lineburg, K. E., Varelias, A., et al. (2011) · Blood · doi:10.1182/blood-2010-12-325746 · Cited by 73
Major depression during interferon-α treatment: vulnerability and prevention
Lotrich, F. E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.4/felotrich · Cited by 72
Trial watch
Vacchelli, E., Aranda, F., Obrist, F., Eggermont, A. M. M., Galon, J., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.29030 · Cited by 64
Self-citation
Critical role for constitutive type I interferon signaling in the prevention of cellular transformation
Chen, H., Tanaka, N., Mitani, Y., Oda, E., Nozawa, H., Chen, J., Yanai, H., Negishi, H., Choi, M. K., Iwasaki, T., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.01051.x · Cited by 63
Trial Watch: Lenalidomide-based immunochemotherapy
Semeraro, M., Vacchelli, E., Eggermont, A. M. M., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26494 · Cited by 61
Self-citation
Expansion of circulating CD56bright natural killer cells in patients with JAK2‐positive chronic myeloproliferative neoplasms during treatment with interferon‐α
Riley, C. H., Hansen, M., Brimnes, M. K., Hasselbalch, H. C., Bjerrum, O. W., Straten, P. T., Svane, I. M., & Jensen, M. K. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12420 · Cited by 59
Interferon-α-secreting mesenchymal stem cells exert potent antitumor effect in vivo
Xu, C., Lin, L., Cao, G., Chen, Q., Shou, P., Huang, Y., Han, Y., Wang, Y., & Shi, Y. (2013) · Oncogene · doi:10.1038/onc.2013.458 · Cited by 57
Targeting IFN-α to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities
Huang, T.-H., Chintalacharuvu, K. R., & Morrison, S. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.10.6881 · Cited by 55
Innate immune sensing of cancer: clues from an identified role for type I IFNs
Gajewski, T. F., Fuertes, M. B., & Woo, S. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1305-6 · Cited by 52
Therapeutic Effect of Human iPS-Cell–Derived Myeloid Cells Expressing IFN-β against Peritoneally Disseminated Cancer in Xenograft Models
Koba, C., Haruta, M., Matsunaga, Y., Matsumura, K., Haga, E., Sasaki, Y., Ikeda, T., Takamatsu, K., Nishimura, Y., & Senju, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067567 · Cited by 50
Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells
Hertler, C., Roth, P., Silginer, M., Florea, A., Lamszus, K., Frei, K., Deenen, R., Reifenberger, G., & Weller, M. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0772 · Cited by 49
The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment
Guillot, B., Portalès, P., Du-Thanh, A., Merlet, S., Dereure, O., Clot, J., & Corbeau, P. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06512.x · Cited by 48
Interferon-α Acts on the S/G2/M Phases to Induce Apoptosis in the G1 Phase of an IFNAR2-expressing Hepatocellular Carcinoma Cell Line
Maeda, S., Wada, H., Naito, Y., Nagano, H., Simmons, S., Kagawa, Y., Naito, A., Kikuta, J., Ishii, T., Tomimaru, Y., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551879 · Cited by 48
Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα+ tumorigenesis
Chan, S. R., Rickert, C. G., Vermi, W., Sheehan, K. C. F., Arthur, C. D., Allen, J. A., White, J. M., Archambault, J. M., Lonardi, S., McDevitt, T. M., et al. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.116 · Cited by 47
Type I IFN gene delivery suppresses regulatory T cells within tumors
Hashimoto, H., Ueda, R., Narumi, K., Heike, Y., Yoshida, T., & Aoki, K. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.60 · Cited by 46
Strict Requirement for Vector-Induced Type I Interferon in Efficacious Antitumor Responses to Virally Encoded IL12
Melero, I., Quetglas, J. I., Reboredo, M., Dubrot, J., Rodríguez-Madoz, J. R., Mancheño, U., Casales, E., Riezu‐Boj, J. I., Ruiz-Guillen, M., Ochoa, M. C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3356 · Cited by 41
Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-α Monotherapy
Ilander, M. M., Kreutzman, A. S., Rohoň, P., Melo, T. P. E., Faber, E., Porkka, K., Vakkila, J., & Mustjoki, S. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087794 · Cited by 41
Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers
Rossi, E. A., Rossi, D. L., Cardillo, T. M., Stein, R., Goldenberg, D. M., & Chang, C. (2011) · Blood · doi:10.1182/blood-2011-03-343145 · Cited by 40
Interferon α may be back on track to treat acute myeloid leukemia
Smits, E., Anguille, S., & Berneman, Z. N. (2013) · OncoImmunology · doi:10.4161/onci.23619 · Cited by 40
The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line
Badgwell, B. D., Lesinski, G. B., MAGRO, C. M. J., Abood, G. J., Skaf, A., & Carson, W. E. (2004) · Journal of Surgical Research · doi:10.1016/j.jss.2003.09.005 · Cited by 35
Interferons in the Treatment of Solid Tumors
Moschos, S. J., Varanasi, S. M., & Kirkwood, J. M. (2005) · Springer eBooks · doi:10.1007/0-387-24361-5_9 · Cited by 33
Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor
Bhattacharya, S., Zheng, H., Tzimas, C., Carroll, M. P., Baker, D. P., & Fuchs, S. Y. (2011) · Blood · doi:10.1182/blood-2010-12-325373 · Cited by 30
hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function
Jiang, W., Zhang, C., Tian, Z., & Zhang, J. (2013) · Gene Therapy · doi:10.1038/gt.2013.31 · Cited by 30
An interferon signature identified by RNA-sequencing of mammary tissues varies across the estrous cycle and is predictive of metastasis-free survival
Snijders, A. M., Langley, S. A., Mao, J., Bhatnagar, S., Bjornstad, K. A., Rosen, C. J., Lo, A. T., Huang, Y., Blakely, E. A., Karpen, G. H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2148 · Cited by 23
The Janus face of cyclophosphamide
Ziccheddu, G., Proietti, E., & Moschella, F. (2013) · OncoImmunology · doi:10.4161/onci.25789 · Cited by 23
Breaking tumor-induced immunosuppression with 5′-triphosphate siRNA silencing TGFβ and activating RIG-I
Schnurr, M. M., & Duewell, P. (2013) · OncoImmunology · doi:10.4161/onci.24170 · Cited by 21
Phosphoinositide 3-kinase regulates a subset of interferon-alpha-stimulated genes
Hjortsberg, L., Lindvall, C. J., Corcoran, M., Arulampalam, V., Chan, D. C. W., Thyrell, L., Nordenskjöld, M., Grandér, D., & Tamm, K. P. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.10.022 · Cited by 19
EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up.
Eggermont, A. M. M., Suciu, S., Santinami, M., Kruit, W. H. J., Testori, A., Marsden, J. R., Punt, C. J. A., Gore, M. E., MacKie, R., Dummer, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.8506b · Cited by 19
Treatment of indolent primary cutaneous B-cell lymphomas with subcutaneous interferon-alfa
Vandersee, S., Terhorst‐Molawi, D., Humme, D., & Beyer, M. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.11.019 · Cited by 18
Treatment with Interferon alpha prior to discontinuation of Imatinib in patients with chronic myeloid leukemia
Hardan, I., Stanevsky, A., Volchek, Y., Tohami, T., Amariglio, N., Trakhtenbrot, L., Koren‐Michowitz, M., Shimoni, A., & Nagler, A. (2011) · Cytokine · doi:10.1016/j.cyto.2011.11.018 · Cited by 17
IFN-β-specific signaling via a unique IFNAR1 interaction
Kaur, S., & Platanias, L. C. (2013) · Nature Immunology · doi:10.1038/ni.2686 · Cited by 17
Interferon-α Treatment for Growing Teratoma Syndrome of the Testis
Inoue, M., Hisasue, S., Nagae, M., China, T., Saito, K., Isotani, S., Yamaguchi, R., Ide, H., Muto, S., & Horie, S. (2013) · Case Reports in Nephrology and Dialysis · doi:10.1159/000350897 · Cited by 12
[Sarcoidosis, myasthenia gravis and anterior ischaemic optic neuropathy: severe side effects of adjuvant interferon-alpha-therapy in malignant melanoma?].
Kreutzer, K., Bonnekoh, B., Franke, I., Ulrich, J., & Gollnick, H. (2004) · PubMed · Cited by 11
Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML)
Zeidner, J. F., Gladstone, D. E., ZAHURAK, M. L., Matsui, W. H., Gocke, C. D., Jones, R. J., & Smith, B. D. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.05.012 · Cited by 11
Low dose of interferon-α improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study
LI, Y.-F., Wang, Q., ZHANG, T.-T., Li, L., WANG, J.-P., Guo-fu, D., & He, D. (2013) · Oncology Letters · doi:10.3892/ol.2013.1653 · Cited by 10
Photodynamische Therapie mit Methylaminooxopentanoat (Metvix®) und einer Breitbandlichtquelle (PhotoDyn 501): Praktische Erfahrungen bei Problem‐Patienten mit Aktinischen Keratosen und Basalzellkarzinomen
Kreutzer, K., Bonnekoh, B., Franke, I., & Gollnick, H. P. M. (2004) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1046/j.1439-0353.2004.04793.x · Cited by 8
Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17 years’ experience in a single centre
Radesi-Sarghi, S., Arbion, F., Dartigeas, C., Delain, M., Benboubker, L., Hérault, O., Colombat, P., & Gyan, E. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1934-7 · Cited by 6

Sorted by citations

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Self-citation
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,520
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Self-citation
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 3,058
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Zhang, Y., & Zhang, Z. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,906

See all 1,305

Authors: Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G.
Affiliations: Université Paris-Sud (FR)
Inserm (FR)
The University of Queensland (AU)
Corresponding author: Kroemer, Guido
ORCID: Zitvogel, Laurence
Galluzzi, Lorenzo
Kepp, Oliver
Smyth, Mark J.
Kroemer, Guido
Venue: Nature Reviews Immunology
Publisher: Springer Science and Business Media LLC
Published: 2015-06-01
Volume: 15
Issue: 7
Pages: 405-414
ISSN: 1474-1733 (ISSN-L)
1474-1741
DOI: 10.1038/nri3845
OpenAlex: W1611944043
Cited by: 1,305
References: 128
Citations by year: 2026: 85 · 2025: 123 · 2024: 162 · 2023: 161 · 2022: 155 · 2021: 121 · 2020: 126 · 2019: 87 · 2018: 104 · 2017: 94 · 2016: 69 · 2015: 17
FWCI: 8.94
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Immunology (publishedVersion)
PubMed (publishedVersion)
Funders: Association pour la Recherche sur le Cancer
Ligue Contre le Cancer
Institut National Du Cancer
Institute of Cancer Research
Topics: Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: type I interferon, antitumor immunity, tumor surveillance, IFN-stimulated genes, oncolytic viruses, immunoadjuvant, chemotherapeutics, targeted anticancer agents, recombinant interferon, cancer immunotherapy
MeSH terms: Animals, Humans, Immunotherapy, Interferon Type I, Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Type I interferons in anticancer immunity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks